Skip to main content

Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

Active, not recruiting · Not applicable · NCT03108456

Conditions: Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction

At a glance

Research payments reported, 2025
$954,002
U.S. investigators named
66
Sites paid
64
Planned or actual enrollment
2,005

About the trial

Sponsor
Abbott Medical Devices (with Cardiovascular Research Foundation, New York)
Tested
Orbital Atherectomy (device), Balloon (device)
Dates
Started 2017-03-27; completion 2025-06-12
Results posted
Not yet

This trial will evaluate Orbital Atherectomy compared to conventional balloon angioplasty technique for the treatment of severely calcified lesions prior to implantation of drug-eluting stents (DES).

From ClinicalTrials.gov, last updated 2023-10-06. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Abbott Laboratories reported $954,002 in research payments for this study in 2025 (154 payments).

Products named: Diamondback Coronary

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.